Company intelligence / Profile preview

Odyssey Group International

Las Vegas, Nevada, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Odyssey Group International—now operating as Odyssey Health, Inc.—is developing novel pharmaceuticals and medical devices targeting neurological conditions and emergency medicine. Its lead program ONP/PRV/ONP‑002 for concussion has completed Phase I single ascending dose studies with positive safety results and demonstrated preclinical efficacy in animal models of brain injury. The company also has a rare disease program for Niemann-Pick disease in preclinical or early development stages[8][9][10].

Therapeutic areas: Neurology
Modalities: Small molecules (neurosteroids)Medical devices
Industry: Biotech

Drug pipeline

1 asset

prv-001

Preclinical

Beyond the preview

Go deeper on Odyssey Group International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Odyssey Group International.

Explore the full profile